Advances in Immuno-Oncology Therapeutics for Metastatic Triple-Negative Breast Cancer

Review the latest developments in immuno-oncology strategies for managing metastatic TNBC with this set of expert commentaries, including optimal use of immune checkpoint inhibition, management of immune-related toxicities, and future directions.

Sarah Donahue, MPH, NP David B. Page, MD Hope S. Rugo, MD Peter Schmid, MD, PhD, FRCP Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 14, 2020 Expired: May 13, 2021

Now that atezolizumab is approved for the treatment of metastatic TNBC, are you informed on how to identify and manage the unique adverse events associated with immune checkpoint inhibition? Read this expert commentary to get up to speed.

Sarah Donahue, MPH, NP Released: March 16, 2020

Now that atezolizumab is approved for the treatment of metastatic TNBC, are you informed on how to best use this agent in your clinical practice? Read this expert commentary to get up to speed.

Hope S. Rugo, MD Released: April 2, 2020

Are you aware of the latest data on immune checkpoint inhibition for the treatment of early-stage TNBC? Read my thoughts on the promise of this strategy for our patients with this disease.

Peter Schmid, MD, PhD, FRCP Released: April 17, 2020

Are you aware of new strategies using combination immunotherapy in the treatment of metastatic TNBC? Read my thoughts on this promising approach to potentially improve response to immunotherapy in these patients.

David B. Page, MD Released: April 27, 2020